Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,709 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $61.03, for a total value of $104,300.27. Following the completion of the sale, the executive vice president owned 46,149 shares in the company, valued at $2,816,473.47. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Andrew Callos also recently made the following trade(s):
- On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total transaction of $156,779.04.
- On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.87, for a total transaction of $1,608,620.00.
- On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00.
- On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The shares were sold at an average price of $62.10, for a total transaction of $55,020.60.
- On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $60.28, for a total transaction of $904,200.00.
- On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The stock was sold at an average price of $62.62, for a total transaction of $112,590.76.
- On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The shares were sold at an average price of $62.44, for a total transaction of $112,953.96.
Cytokinetics Price Performance
Shares of CYTK stock opened at $60.83 on Tuesday. The company's fifty day simple moving average is $63.91 and its two-hundred day simple moving average is $60.74. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The stock has a market capitalization of $7.49 billion, a price-to-earnings ratio of -9.32 and a beta of 0.56.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analysts' expectations of $8.02 million. Cytokinetics's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.26) earnings per share. Equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.
Wall Street Analysts Forecast Growth
CYTK has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on Cytokinetics from $95.00 to $101.00 and gave the stock an "outperform" rating in a research note on Friday, February 20th. Truist Financial upped their price target on Cytokinetics from $84.00 to $92.00 and gave the company a "buy" rating in a research report on Tuesday, February 3rd. Citigroup reissued a "market outperform" rating on shares of Cytokinetics in a report on Monday, December 22nd. Citizens Jmp boosted their price objective on shares of Cytokinetics from $88.00 to $96.00 and gave the company a "market outperform" rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley set a $90.00 target price on shares of Cytokinetics in a report on Thursday, January 8th. Seventeen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cytokinetics currently has a consensus rating of "Moderate Buy" and a consensus price target of $89.00.
Read Our Latest Stock Analysis on CYTK
Institutional Trading of Cytokinetics
A number of hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can grew its position in Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company's stock worth $845,000 after acquiring an additional 160 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in Cytokinetics by 1.2% during the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company's stock worth $838,000 after purchasing an additional 162 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Cytokinetics by 10.6% in the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 169 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 171 shares in the last quarter. Finally, Vident Advisory LLC increased its position in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company's stock valued at $1,046,000 after purchasing an additional 234 shares during the last quarter.
About Cytokinetics
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
